Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.32 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513900 | 0.83 | CYP3A4 (0.38) | DYRK1A | |
| Urea SCHEMBL5444104 | 0.81 | CYP3A4 (0.37) | DYRK1A | |
| SCHEMBL18114338 | 0.80 | CYP3A4 (0.33) | — | |
| SCHEMBL1696064 | 0.80 | CYP3A4 (0.33) | — | |
| SCHEMBL10679044 | 0.77 | GRM5 (0.36) | — | |
| SCHEMBL21187 | 0.76 | KDM4E (0.47) | — | |
| Acrylamide SCHEMBL29208545 | 0.75 | BTK (0.36) | — | |
| SCHEMBL1827089 | 0.74 | KDM4E (0.46) | — | |
| Methane SCHEMBL27916786 | 0.74 | KDM4E (0.46) | — | |
| N4-Hydroxycytosine SCHEMBL48396 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2006-07-06 | — | — | US | disclosed |
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2006-07-06 | — | — | US | disclosed |
| US-6811595-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-6811595-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | RPP30, INO80, CDK20 | F2 3681/4885DYRK1A 2885/4885KLK1 3143/4885 |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | CCNI, INO80, CCNY | F2 1987/4885DYRK1A 3513/4885KLK1 3428/4885 |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | F2 3715/4885DYRK1A 2584/4885KLK1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.